# Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization

> **NCT03042871** · PHASE4 · COMPLETED · sponsor: **Zhongshan Ophthalmic Center, Sun Yat-sen University** · enrollment: 54 (actual)

## Conditions studied

- Choroidal Neovascularization

## Interventions

- **DRUG:** 0.5mg intravitreal ranibizumab

## Key facts

- **NCT ID:** NCT03042871
- **Lead sponsor:** Zhongshan Ophthalmic Center, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2018-07
- **Final completion:** 2018-07
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2019-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03042871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03042871, "Dosing Strategy of Intravitreal Ranibizumab for Pathological Myopia Choroidal Neovascularization". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03042871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*